Novo Nordisk says Catalent buyout to close soon

Novo Nordisk says Catalent buyout to close soon as regulatory conditions met
Novo Nordisk (NVO) announced Saturday that its pending acquisition of three Catalent (NYSE:CTLT) production sites is expected to close within days as its parent entity satisfied all regulatory conditions to buy the U.
Novo Nordisk Set to Close Catalent Deal Without FTC Challenge
(Bloomberg) -- Novo Nordisk A/S can advance with its acquisition of factories from contract development and manufacturing organization Catalent Inc. after the Federal Trade Commission declined to challenge the deal. The parties are free to close the ...
Novo says Catalent deal regulatory closing conditions fulfilled
Novo Nordisk (NVO) announced that as of today, all regulatory closing conditions relating to the review of its pending acquisition of Catalent
Novo’s $16.5bn Catalent deal cleared by EU Commission
Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not create competition issues and can go ahead, according to the European Commission.
European regulators approve $16.5 billion deal for Novo Holdings to buy Catalent
The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of Novo Nordisk, one of the
Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Indiana Daily Student1d
Novo’s takeover of Catalent set to proceed after FTC declines to challenge deal
Novo Holdings will proceed with its $16.5 billion acquisition of Catalent, the companies announced Saturday, after the ...
DPA International on MSN1d
Ozempic maker Novo Nordisk to boost production through acquisition
Danish pharma company Novo Nordisk, makers of weight-loss drugs Ozempic and Wegovy, plans to expand production based on a ...
Novo Holdings’ acquisition of Catalent gains EC approval
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...
Indiana Daily Student11d
What Novo’s takeover of Catalent could mean for Bloomington workers
Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...
BioSpace6d
Novo, Catalent $16.5B Deal Wins EU Blessing as US Antitrust Scrutiny Mounts
In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...
24/7 Wall St2d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk to boost production with a new acquisition
Danish pharma giant Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, is set to boost production with a ...